<DOC>
	<DOCNO>NCT02016729</DOCNO>
	<brief_summary>Open-label , sequential dose escalation expansion study AMG 232 subject acute myeloid leukemia .</brief_summary>
	<brief_title>A Phase 1b Study Evaluating AMG 232 Alone Combination With Trametinib Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Men woman &gt; 18 year old Pathologicallydocumented , definitivelydiagnosed AML relapse refractory standard treatment , standard therapy available subject refuse standard therapy Ability take oral medication willing record daily adherance investigational product Adequate hematological , renal , hepatic , coagulation laboratory assessment Active infection require intravenous ( IV ) antibiotic Prior participation investigational study ( procedure device ) within 21 day study day 1 Major surgery within 28 day study day 1 Antitumor therapy within 14 day study day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AML</keyword>
</DOC>